title: Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry.
abstract: BACKGROUND
  Studies of cardiomyopathy in children with Noonan syndrome (NS) have been primarily small case series or cross-sectional studies with small or no comparison groups.
  
  
  METHODS
  We used the Pediatric Cardiomyopathy Registry database to compare the survival experience of children with NS and hypertrophic cardiomyopathy (HCM) with children with idiopathic or familial HCM and to identify clinical and echocardiographic predictors of clinical outcomes.
  
  
  RESULTS
  Longitudinal data in 74 children with NS and HCM and 792 children with idiopathic or familial isolated HCM were compared. Children with NS were diagnosed with HCM before 6 months old more often (51%) than children with HCM (28%) and were more likely to present with congestive heart failure (CHF) (24% vs 9%). The NS cohort had lower crude survival than the group with other HCM (P = .03), but survival did not differ after adjustment for CHF and age at diagnosis. Within the NS cohort (1-year survival 78%), a diagnosis of HCM before age 6 months with CHF resulted in 31% 1-year survival. Lower height-for-age z score (hazard ratio 0.26, P = .005) in place of CHF and lower left ventricular fractional shortening z score (hazard ratio 0.79, P = .04) also independently predicted mortality.
  
  
  CONCLUSIONS
  Patients with NS with HCM have a worse risk profile at presentation compared with other children with HCM, resulting in significant early mortality (22% at 1 year). Decreased height-for-age and lower, although still supranormal, left ventricular fractional shortening z score are independent predictors of mortality in patients with NS with HCM. Such patients should have an aggressive therapeutic approach including potential listing for cardiac transplantation.
authors.affiliation: University of Miami Miller School of Medicine, FL, USA.
authors.forename: James D
authors.initials: JD
authors.lastname: Wilkinson
authors.forename: April M
authors.initials: AM
authors.lastname: Lowe
authors.forename: Bonnie A
authors.initials: BA
authors.lastname: Salbert
authors.forename: Lynn A
authors.initials: LA
authors.lastname: Sleeper
authors.forename: Steven D
authors.initials: SD
authors.lastname: Colan
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Cox
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Towbin
authors.forename: David M
authors.initials: DM
authors.lastname: Connuck
authors.forename: Jane E
authors.initials: JE
authors.lastname: Messere
authors.forename: Steven E
authors.initials: SE
authors.lastname: Lipshultz
mesh_terms: D000367:Age Factors; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000209:etiology / Q000401:mortality*; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006352:Heart Ventricles / Q000473:pathology; D006801:Humans; D007223:Infant; D008137:Longitudinal Studies; D008297:Male; D009634:Noonan Syndrome / Q000150:complications / Q000175:diagnosis / Q000401:mortality*; D012042:Registries; D012307:Risk Factors; D015996:Survival Rate